Peptides for Weight Loss: What Actually Works (and What Doesn't)

You've probably seen the word "peptide" attached to everything from Ozempic to gray-market injections sold by fitness influencers. Both are technically peptides. But they have about as much in common as aspirin and fentanyl.

If you're researching peptides for weight loss, the first thing you need is an honest overview: not a sales pitch, not a scare story, just a clear breakdown of what's FDA-approved, what's research-only, what has real clinical data behind it, and what failed Phase 3 trials and quietly disappeared.

That's what this guide covers.

What Are Peptides and How Do They Work for Weight Loss?

Peptides are short chains of amino acids, smaller than proteins, built to signal specific biological functions. Your body already makes hundreds of them. The ones used in weight management work by targeting the hormonal systems that regulate hunger, fullness, metabolism, and fat storage.

The most important category is GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating. If you want a deeper look at what peptides are and how they work at the biochemical level, What Are Peptides covers the fundamentals. It tells your brain you're full, slows how fast your stomach empties, and helps regulate insulin. The weight loss medications you keep hearing about (semaglutide, tirzepatide, liraglutide) are synthetic peptides engineered to mimic and extend this signal.

GH secretagogues like CJC-1295 and tesamorelin work differently. They trigger your pituitary gland to release more growth hormone, which shifts your body toward burning fat and building muscle. That's the theory. The human evidence, as we'll cover, varies dramatically by compound.

Understanding which pathway a peptide targets matters. Because the mechanisms are different, the results, risks, and regulatory status are also completely different.

The Evidence Gradient: Where Each Peptide Actually Stands

Not all peptides for weight loss are equal. There's a clear evidence gradient, from compounds backed by enormous randomized controlled trials to compounds that failed their clinical tests entirely. Knowing where something sits on that gradient should determine how seriously you take it.

Semaglutide and tirzepatide sit at the top. They're FDA-approved for weight management, with trial data from thousands of participants published in major journals. This is the strongest level of clinical evidence available.

Tesamorelin is FDA-approved, but only for one narrow indication (HIV-associated lipodystrophy). For general weight loss, it's off-label with limited trial data outside that specific population.

CJC-1295 and ipamorelin have no FDA approval for any indication. Incretin-based therapies remain the dominant evidence-based approach for weight management (Lovshin et al., 2009). Human data on weight loss is sparse for GH secretagogues. What exists is mostly in diabetes or GH-deficiency populations, not healthy adults.

AOD-9604 never made it to market. It failed Phase 3 clinical trials for obesity and was never approved. It's now sold as a "research compound," a legal gray zone, not a vetted medication.

That gradient matters before you sign up for anything.

Semaglutide: The Clinical Benchmark

Semaglutide is the most studied peptide for weight loss in history. If you want to understand what real clinical evidence looks like in this space, start here.

The STEP 1 trial enrolled 1,961 adults without diabetes and treated them with weekly 2.4 mg semaglutide injections for 68 weeks. Mean body weight reduction was 14.9% — roughly 30 pounds if you start at 200 (Wilding et al., 2021). That's not a before-and-after photo on Instagram. That's a peer-reviewed trial in the New England Journal of Medicine.

Earlier phase 2 data comparing semaglutide to liraglutide showed semaglutide producing significantly more weight loss at equivalent doses (ONeil et al., 2018), which is partly why it became the preferred option.

GLP-1 receptor agonists are now recommended as the preferred first injectable medication for metabolic disease based on their weight and cardiovascular outcomes profile (Davies et al., 2018). The first tirzepatide proof-of-concept also came from Frias et al. (2018), demonstrating dual receptor activation. Semaglutide is sold as Wegovy for weight management and Ozempic for type 2 diabetes. Both are FDA-approved. Wegovy is specifically labeled for chronic weight management in adults with a BMI of 30+, or 27+ with a weight-related condition. GLP-1 agonists also showed reduced alcohol intake in a recent Ireland trial (2026), adding to the growing list of metabolic benefits beyond weight loss.

One critical update: compounded semaglutide, which many telehealth companies were prescribing at lower cost during the shortage era, is largely gone. The FDA shortage resolution (FDA, 2024-2025) effectively ended legal compounding for most pharmacies. If someone is still offering you "compounded semaglutide" at a steep discount, ask questions.

WADA status: Semaglutide is NOT on the WADA prohibited list. Competitive athletes can use it under physician supervision.

Tirzepatide: The New Leader

Tirzepatide is the first medication that activates two appetite-regulating pathways at once: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The weight loss numbers from trials are the most impressive of any approved medication in this class.

The SURMOUNT-1 trial enrolled 2,539 adults with obesity and randomized them to tirzepatide 5 mg, 10 mg, 15 mg, or placebo for 72 weeks. The 15 mg group lost a mean of 22.5% of body weight versus 2.4% with placebo (Jastreboff et al., 2022). At 200 pounds starting weight, that's over 45 pounds.

A notable subset of patients (roughly 37% at the highest dose) lost more than 25% of their body weight (Jastreboff et al., 2022). That's in the range of what some bariatric surgical procedures produce.

The first tirzepatide data came from Frias et al. (2018), who showed the dual GIP/GLP-1 mechanism outperformed GLP-1 alone on both glycemic control and weight. Tirzepatide is sold as Mounjaro for type 2 diabetes (FDA-approved 2022) and Zepbound for weight management (FDA-approved November 2023). Like semaglutide, the compounding era for tirzepatide is largely over. The FDA removed it from the shortage list in 2024.

WADA status: NOT prohibited.

Liraglutide: The Earlier GLP-1

Liraglutide (Saxenda) was the first GLP-1 approved specifically for weight management, gaining FDA approval in 2014. It works on the same pathway as semaglutide but has a shorter half-life, requiring daily injections rather than weekly.

The SCALE trial tested 3 mg liraglutide in 3,731 participants without type 2 diabetes over 56 weeks. Mean weight loss was 8.4 kg versus 2.8 kg with placebo — roughly 12 lbs at a 150-lb starting weight (Pi-Sunyer et al., 2015). PIONEER 4 data (Pratley et al., 2019) also confirmed GLP-1 efficacy across oral and injectable formulations. Meaningful, but significantly less than what semaglutide and tirzepatide produce.

Most providers who prescribe GLP-1s today start with semaglutide or tirzepatide given the superior efficacy data and the once-weekly dosing that makes adherence easier. Liraglutide remains an option for patients who don't tolerate the weekly injectables.

Tesamorelin: Approved, But With Strings Attached

Tesamorelin is a growth hormone releasing hormone (GHRH) analog that stimulates your pituitary to release more GH. It's FDA-approved under the brand name EGRIFTA SV.

Here's the catch: it's approved only for excess visceral fat in HIV-positive patients on antiretroviral therapy. Not for general weight loss. Not for body composition in healthy adults. That specific, narrow indication.

Off-label, some physicians prescribe it for visceral fat reduction in non-HIV patients. There is mechanistic logic to this. Elevated GH does shift body composition toward less visceral fat and more lean mass. But the human RCT data outside the HIV population is limited, and the FDA label doesn't cover general use.

If a provider offers you tesamorelin for weight loss without noting it's off-label, ask why.

WADA status: PROHIBITED. Tesamorelin falls under the S2 category (GH peptide secretagogues). Competitive athletes cannot use it.

CJC-1295 and Ipamorelin: The Research Compounds

CJC-1295 and ipamorelin are often stacked together in what's marketed as a "GH peptide stack" (CJC-1295 is a GHRH analog, ipamorelin is a ghrelin mimetic, and together they're supposed to produce a more sustained GH pulse than either alone). You'll also sometimes see sermorelin recommended for similar purposes. Sermorelin Before and After covers the realistic expectations for that compound.

You'll find them aggressively marketed at wellness clinics. Here's what the actual evidence shows: there are no FDA-approved indications, no large randomized trials in healthy adults for weight loss, and no regulatory approval for compounding for this specific purpose.

What exists is mostly small studies in GH-deficient patients, some data on body composition in older adults, and a lot of extrapolation. Researchers have documented how GLP-1 pathways drive weight loss through rigorous trials (Zinman et al., 2009) and incretin mechanism reviews (Lovshin et al., 2009) — but the GH secretagogue literature is nowhere close to that level of evidence for weight loss specifically.

CJC-1295/ipamorelin is available through some compounding pharmacies. Whether it's legally compoundable under current FDA guidance is a genuinely complicated question — the FDA has been tightening rules on 503A/503B pharmacies and added many peptides to restricted lists beginning in 2023.

WADA status: PROHIBITED. GH secretagogues fall under S2. Not for competitive athletes.

For everyday patients researching peptides for weight loss, this combination makes less sense than starting with an FDA-approved option that has strong trial evidence behind it.

AOD-9604: The One That Failed

AOD-9604 is a fragment of human growth hormone, developed in the early 2000s with serious backing. The idea was to isolate the fat-burning activity of GH without the blood sugar effects. It's sometimes compared to other peptides like BPC-157, though that compound targets tissue repair rather than fat metabolism. See BPC-157 Benefits for how they differ. The preclinical data on AOD-9604 looked promising.

It went into clinical trials for obesity. It failed.

The Phase 3 trials showed it did not produce meaningful weight loss compared to placebo at the doses tested. AOD-9604 was ultimately classified as a non-approved substance under WADA's S0 category (WADA, 2024). No FDA approval followed. The compound is now sold as a "research peptide" — legally available for research purposes, not for human consumption as a weight loss agent.

Some wellness providers still offer it. That should give you pause. Telling a patient "this compound failed Phase 3 obesity trials but we're offering it anyway" is not a conversation most clinics want to have.

Comparing Peptides for Weight Loss Side by Side

Peptide	FDA-Approved for Weight Loss?	Avg Trial Weight Loss	WADA Status	Evidence Level
Semaglutide (Wegovy)	Yes	~15% body weight	Not prohibited	Large RCTs
Tirzepatide (Zepbound)	Yes	~22% body weight	Not prohibited	Large RCTs
Liraglutide (Saxenda)	Yes	~8% body weight	Not prohibited	Large RCTs
Tesamorelin	Off-label only	Limited human data	PROHIBITED	Narrow RCTs (HIV only)
CJC-1295/Ipamorelin	No	No human RCT data	PROHIBITED	Research only
AOD-9604	No	Failed Phase 3	PROHIBITED	Failed trials

Side Effects of Peptides for Weight Loss

GLP-1 medications have a well-documented safety profile — well-documented because tens of millions of people have taken them, and the FDA FAERS database has 78,284 adverse event reports on file (FDA FAERS, 2024). That number reflects usage scale, not unusual danger.

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. The ADA/EASD consensus (Davies et al., 2018) classified GLP-1 receptor agonists as generally well-tolerated and suitable as first injectable medications for metabolic disease. These effects are typically dose-related and most pronounced during the titration phase as your dose ramps up. Most patients find them manageable and improving over time.

Serious but rare risks include pancreatitis and gallbladder disease. There is also a theoretical risk of thyroid C-cell tumors seen in rodent studies. This is why GLP-1 medications carry a black box warning and should not be used by people with a personal or family history of medullary thyroid carcinoma or MEN2.

For GH secretagogues like CJC-1295 and tesamorelin, side effects can include water retention, joint pain, carpal tunnel symptoms, and elevated blood glucose. The GDF15 pathway is a separate mechanism now under investigation for obesity pharmacotherapy, with early data showing appetite suppression independent of GLP-1 (Wang et al., 2021). Pi-Sunyer et al. (2015) established liraglutide as the first GLP-1 approved for weight management, setting the template for the drugs that followed. The risk profile is different and still being characterized because the human data is more limited.

AOD-9604 has minimal long-term human safety data. That's not reassuring when it's the entire point.

Cost, Insurance, and Access

Peptides for weight loss span a wide range of cost and accessibility. Here's what to expect.

FDA-approved GLP-1s: Wegovy (semaglutide) has a list price around $1,300-1,400 per month. Zepbound (tirzepatide) is similar. Insurance coverage varies widely. Some plans cover it for obesity, others require documented failure of other treatments, and many simply don't cover weight management medications. Novo Nordisk and Eli Lilly both have savings programs that can reduce out-of-pocket cost for eligible patients, though these programs have income and insurance restrictions.

Saxenda (liraglutide) is generally less expensive than the newer weekly injectables, though still not cheap.

Research peptides: CJC-1295/ipamorelin through a compounding pharmacy typically runs $100-400 per month depending on the supplier and dosing. Tesamorelin is in a similar range for compounded versions. These are almost never covered by insurance.

At HEXIS, we work with patients on both FDA-approved options and, where appropriate, peptide protocols. Your provider evaluates your labs, goals, and history before recommending anything. The starting point is always your numbers, not a one-size-fits-all prescription. Schedule a consultation to see what makes sense for your situation.

The Compounding Question

For the past several years, compounded semaglutide and tirzepatide were widely available because the FDA had placed the brand-name versions on the drug shortage list. That opened the door for 503A and 503B compounding pharmacies to produce their own versions at significantly lower cost.

That window is mostly closed. The FDA removed Ozempic and Wegovy from the shortage list in March-April 2025. Mounjaro and Zepbound were removed in 2024. Under FDA regulations, once a drug is removed from the shortage list, compounding pharmacies can no longer produce copies in most circumstances.

Some compounders have pushed back and continue operating. This is a legally contested area. But patients should understand that compounded GLP-1s now exist in a murky legal space. The door the shortage period opened is largely shut.

If you're currently on compounded semaglutide, talk to your provider about your options before your pharmacy stops being able to fill it.

Frequently Asked Questions

Which peptide is best for weight loss?

For patients without a contraindication, tirzepatide (Zepbound) currently shows the strongest weight loss results of any approved option — averaging around 22% body weight reduction in the SURMOUNT-1 trial (Jastreboff et al., 2022). Semaglutide (Wegovy) is close behind at ~15%. Both are FDA-approved. The "best" option for any individual depends on their health history, insurance coverage, and tolerance.

Are peptide injections for weight loss safe?

FDA-approved GLP-1 injections (semaglutide, tirzepatide, liraglutide) have well-documented safety profiles from large clinical trials. Common side effects are GI-related and dose-dependent. Serious risks exist but are rare. Research compounds like CJC-1295, tesamorelin, and AOD-9604 have much less human safety data and are not FDA-approved for weight loss. Safety can't be assumed when trials haven't been run.

Can you get weight loss peptides without a prescription?

FDA-approved GLP-1 medications require a prescription. Some research peptides are technically available without one through gray-market suppliers — but that doesn't mean they're legal for human consumption, safe, or what they claim to be. Physician oversight exists for a reason: dosing, contraindications, and monitoring all matter.

Does insurance cover weight loss peptides?

Coverage for FDA-approved medications like Wegovy and Zepbound varies by plan. Some insurers cover them for obesity with documented BMI criteria; others don't. Medicare Part D has historically excluded weight loss drugs, though recent legislation has begun changing that. Research peptides are almost never covered. Manufacturer savings programs can help with brand-name GLP-1 costs for eligible patients.

Can athletes use weight loss peptides?

GLP-1 medications (semaglutide, tirzepatide, liraglutide) are NOT prohibited by WADA. Competitive athletes can use them under physician supervision. GH secretagogues — including CJC-1295, ipamorelin, and tesamorelin — ARE prohibited under WADA's S2 category. AOD-9604 is also prohibited. If you're a competitive athlete at any level with drug testing, ask your provider specifically about WADA status before starting anything.

Your Next Step

The honest answer to "which peptide should I take for weight loss" is: it depends on your baseline, your goals, your health history, and what's actually legal and accessible right now. Most patients who do well with peptides for weight loss are on an FDA-approved GLP-1 started at a therapeutic dose with proper titration and physician oversight.

If you're trying to figure out which peptide for weight loss fits your situation — or whether peptide therapy makes sense at all — your HEXIS provider will look at your full picture before making any recommendation. No guesswork. Schedule a consultation and we'll start with your labs.